openPR Logo
Press release

OTC Analgesics Sales Bolster with Continued Improvements from Prime Manufacturers, reports Fact.MR Study | Major Players - Sun Pharmaceuticals Industries Limited, Johnson & Johnson Service, AstraZeneca Plc., Reckitt Benckiser Group Plc., Novartis AG

05-20-2019 10:40 AM CET | Health & Medicine

Press release from: Fact.MR

OTC Analgesics Sales Bolster with Continued Improvements from

Analgesics are counter pain drugs, which stop the pain sensation for some time, or completely eliminate the feeling of pain. These drugs are often consumed by individuals, without the need for any necessary prescription, for type of pain which reoccurs or is of less degree. The drugs which don’t require prescription fall under OTC analgesics, for example drugs for reducing fever, or body pain killers.

Get Sample Copy of this Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=75

The advent of healthcare reforms, and favorable regulatory norms worldwide, have encouraged the initiation & uptake of several pain management programs, in a bid to reduce the overall healthcare costs. For example, Patient Protection and Affordable Care Act of the U.S. has provisions for pain management. These instances have paved ways for developing effective OTC analgesics. OTC analgesic drugs are usually purchased in large quantities, with wide availability of drugs for relieving various types of pain in distribution stores. These factors are expected to influence growth of the global OTC analgesics market.

The trend of utilizing off-label drugs, which are unapproved and affordable medications effective for treatment of diseases, has been gaining an uptick over the recent past. Management of symptoms related to pain has become easy and convenient owing to the availability of OTC analgesics, and these are further prescribed with approved drugs as the maintenance therapies. There is a high potential for growth of the global OTC analgesics market, with sales and demand for pain medication such as pain killers, or pain relievers gaining a significant prevalence among individuals. In addition, demand for non-narcotic pain medication has been witnessing a surge on the back of ill effects associated with narcotic drugs on patients. Topical analgesic manufacturers as well as distributor are increasing their product portfolio to gain huge profits from opportunities in the developed as well as developing markets.

The global OTC analgesics market is projected to register a steady expansion through 2022. The market is estimated to surpass revenues worth US$ 20,000 Mn by 2022 end.

Browse Complete Market Report with TOC Here @ https://www.factmr.com/report/75/otc-analgesics-market

Pharmacy to Remain the Most Lucrative OTC Channel in the Global OTC Analgesics Market

Pharmacy will remain the most lucrative OTC channel for sales of OTC analgesics in the market. Drug store is expected to be the second largest OTC channel in the market. OTC analgesics sales in online store, and the modern trade OTC channels will register the fastest expansion through 2022.

North America will continue to account for the largest revenue share of the market, and is estimated to retain its dominance in the global OTC analgesics market over the forecast period. In addition, Europe will remain the second most lucrative market for OTC analgesics, however the market in Japan will register a relatively faster expansion than in Europe through 2022.

OTC analgesics in the form of tablets will account for more than half revenue share of the market over the forecast period. In addition, tablet OTC analgesics are anticipated to remain sought-after among consumers around the world. Capsule will continue to be the second largest sold OTC analgesics product in the global market, with sales expanding at the highest CAGR throughout the forecast period.

Competition Tracking

Key market players mentioned in Fact.MR’s report include Sun Pharmaceuticals Industries Limited, Johnson & Johnson Service, Inc., AstraZeneca Plc., Reckitt Benckiser Group Plc., Novartis AG, GlaxoSmithKline Plc., and Pfizer Inc.

For any query, connect with an Analyst @ https://www.factmr.com/connectus/sample?flag=AE&rep_id=75

About Fact.MR

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us            
Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
Blog: https://factmrblog.com/
Read Industry News at - https://www.industrynewsanalysis.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release OTC Analgesics Sales Bolster with Continued Improvements from Prime Manufacturers, reports Fact.MR Study | Major Players - Sun Pharmaceuticals Industries Limited, Johnson & Johnson Service, AstraZeneca Plc., Reckitt Benckiser Group Plc., Novartis AG here

News-ID: 1745017 • Views:

More Releases from Fact.MR

Hemoglobinopathy Market Forecast Growing at 8.3% CAGR to Reach $1.7 Billion by 2034
04-24-2024 | Health & Medicine
Fact.MR
Hemoglobinopathy Market Forecast Growing at 8.3% CAGR to Reach $1.7 Billion by 2 …
In 2024, the global hemoglobinopathy market (ヘモグロビン症市場) is estimated to be worth US$788.1 million, with a projected compound annual growth rate (CAGR) of 8.3% through 2034. By 2034, the market size is expected to exceed US$1,745.7 million. The rise of genetic testing has led to a significant shift in the hemoglobinopathy market towards personalized medication. Companies are leveraging this trend to develop tailored treatment plans based on each patient's DNA
Sales Forecast of Elder Care Product Market to Reach US$ 56.7 Billion by 2034 with a 6.7% CAGR
04-24-2024 | Health & Medicine
Fact.MR
Sales Forecast of Elder Care Product Market to Reach US$ 56.7 Billion by 2034 wi …
The global elder care product market (高齢者介護製品市場) is anticipated to reach a value of US$ 29,600.2 million by 2024 and is expected to exceed US$ 56,719.4 million by 2034. Sales of these products are forecasted to grow at a CAGR of 6.7% through 2034, driven by the growing trend of aging-in-place. This trend is fueling innovations in technology integration, wearable health devices, and personalized safety solutions. Increasing awareness about elder
Veterinary Oncology Market Predicts 12% CAGR Through 2033 With a US$ 800 Million
04-24-2024 | Health & Medicine
Fact.MR
Veterinary Oncology Market Predicts 12% CAGR Through 2033 With a US$ 800 Million
In 2023, the veterinary oncology market (獣医腫瘍学市場) was valued at US$ 260 million, and it's anticipated to reach US$ 800 million by the end of 2033, with a projected compound annual growth rate (CAGR) of 12% from 2023 to 2033. Veterinary oncology focuses on caring for pets diagnosed with cancer, with the goal of enhancing their overall quality of life. Cancer is the leading cause of mortality among companion animals,
Sales of Luxury Eyewear are forecasted to reach US$ 56 billion by 2033
Sales of Luxury Eyewear are forecasted to reach US$ 56 billion by 2033
According to Fact.MR, a trusted provider of market research and competitive intelligence, the global Luxury Eyewear Market was valued at US$ 40 billion in 2023. Projections suggest that by the conclusion of 2033, this market is anticipated to escalate to US$ 56 billion. Forecasts indicate a steady Compound Annual Growth Rate (CAGR) of 3.4% in the global demand for luxury eyewear from 2023 to 2033. The surge in luxury eyewear sales

All 5 Releases


More Releases for OTC

Deadline on Nov. 9th upcoming in Lawsuit for Investors in Harborside Inc. (OTC: …
The Shareholders Foundation announced that a deadline is coming up on November 9, 2020 in the lawsuit filed for certain investors of Harborside Inc. (OTC: HSDEF, OTC: HBORF). Investors who purchased shares of Harborside Inc. (OTC: HSDEF, OTC: HBORF) have certain options and there are strict and short deadlines running. Deadline: November 9, 2020. Harborside Inc. stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. According to
Investigation for Long-Term Investors in shares of Volkswagen AG (OTC: VWAGY / O …
An investigation on behalf of current long-term investors in shares of Volkswagen AG (OTC: VWAGY / OTC: VLKAF / OTC: VWAPY) was announced over potential breaches of fiduciary duties by certain officers and directors at Volkswagen AG. Investors who purchased shares of Volkswagen AG (OTC: VWAGY / OTC: VLKAF / OTC: VWAPY) and currently hold any of those Volkswagen AG shares have certain options and should contact the Shareholders Foundation at
OTC: VWAGY / OTC: VLKAF / OTC: VWAPY Shareholder Notice: Update in Lawsuit again …
The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in Volkswagen AG (OTC: VWAGY) (OTC: VWAPY) shares. Investors, who purchased shares of Volkswagen AG (OTC: VWAGY) (OTC: VLKAF) (OTC: VWAPY), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. On September 25, 2015, a lawsuit was filed against Volkswagen AG (alleged securities laws violations. The plaintiff claimed that the defendants
OTC Analgesics Market OTC analgesics market is projected to register a steady ex …
About OTC Analgesics Market The global OTC analgesics market is projected to register an above-average CAGR during 2017 to 2022. Global sales of OTC analgesics is estimated to account for nearly US$ 25,000 Mn revenues by 2022-end. Get Sample copy of this Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=75 The trend of using off-label drugs that are affordable and unapproved, but effective in treating diseases, has been witnessing an upsurge over the past few years.
03-14-2018 | Health & Medicine
Fact.MR
OTC Analgesics Market Report 2017-22: Pharmacy to Remain the Most Lucrative OTC …
A fresh study, covering “OTC Analgesics Market Forecast, Trend Analysis & Competition Tracking – Global Review 2017 to 2022” has been broadcasted to wide online repository of Fact MR, which presents deep focus on the healthcare market. This smart study contains precise data that offers a clear insight about market current scenario and future projections for the benefit of readers. Moreover, the study enclosed significant data which tends to make
The OTC Drugs Market: Commercial Trends and Rx-to-OTC Switch Prospects
ReportsWeb.com has announced the addition of the “Global OTC Drugs Market Research Report 2017” The report focuses on global major leading industry players with information such as company profiles, product picture and specification. GBI Research's latest report, "The OTC Drugs Market: Commercial Trends and Rx-to-OTC Switch Prospects" discusses trends in the over-the-counter (OTC) pharmaceuticals market and the commercial prospects for switching drugs from prescription-only to OTC status. The report assesses current